JP2006522817A5 - - Google Patents

Download PDF

Info

Publication number
JP2006522817A5
JP2006522817A5 JP2006509864A JP2006509864A JP2006522817A5 JP 2006522817 A5 JP2006522817 A5 JP 2006522817A5 JP 2006509864 A JP2006509864 A JP 2006509864A JP 2006509864 A JP2006509864 A JP 2006509864A JP 2006522817 A5 JP2006522817 A5 JP 2006522817A5
Authority
JP
Japan
Prior art keywords
bowel syndrome
irritable bowel
formulation
pharmaceutical formulation
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006509864A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006522817A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/010996 external-priority patent/WO2004091622A1/en
Publication of JP2006522817A publication Critical patent/JP2006522817A/ja
Publication of JP2006522817A5 publication Critical patent/JP2006522817A5/ja
Pending legal-status Critical Current

Links

JP2006509864A 2003-04-08 2004-04-08 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用 Pending JP2006522817A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46160803P 2003-04-08 2003-04-08
PCT/US2004/010996 WO2004091622A1 (en) 2003-04-08 2004-04-08 The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome

Publications (2)

Publication Number Publication Date
JP2006522817A JP2006522817A (ja) 2006-10-05
JP2006522817A5 true JP2006522817A5 (https=) 2007-06-07

Family

ID=33299841

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006509864A Pending JP2006522817A (ja) 2003-04-08 2004-04-08 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用

Country Status (10)

Country Link
US (1) US20050004155A1 (https=)
EP (1) EP1617846A1 (https=)
JP (1) JP2006522817A (https=)
CN (1) CN1767830A (https=)
AU (1) AU2004229462A1 (https=)
BR (1) BRPI0409128A (https=)
CA (1) CA2521369A1 (https=)
MX (1) MXPA05010819A (https=)
RU (1) RU2373936C2 (https=)
WO (1) WO2004091622A1 (https=)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
EP1638607A1 (en) * 2003-04-08 2006-03-29 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
CA2811272C (en) * 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
JP2005239696A (ja) * 2004-01-30 2005-09-08 Daiichi Suntory Pharma Co Ltd 無機物質を配合した医薬硬質カプセル剤
EP1845989A1 (en) * 2005-01-20 2007-10-24 Progenics Pharmaceuticals, Inc. Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US20060269507A1 (en) * 2005-05-27 2006-11-30 Susan Fuller Topical ointment compostion and method for making the same
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
GB0611240D0 (en) * 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
CO5790164A1 (es) * 2006-08-10 2007-08-31 Procaps S A Composicion farmaceutica solida que incluye en combinacion un agente regulador de la motilidad intestinal y un agente antiflatulento
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
JP2010522756A (ja) * 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
PL2137191T3 (pl) * 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
EP2565195B1 (en) * 2007-03-29 2015-05-06 Wyeth LLC Peripheral opioid receptor and antagonists and uses thereof
CA2682608A1 (en) 2007-03-30 2008-10-09 Tioga Pharmaceuticals, Inc. Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
CA2681582C (en) 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
JP5905198B2 (ja) * 2007-10-01 2016-04-20 ザ ユニヴァーシティー オヴ シカゴ 薬剤誘発性吐き気のオピオイド拮抗薬による治療
JP2011500853A (ja) * 2007-10-25 2011-01-06 ファィトシューティカ， インコーポレイテッド 炎症性腸疾患および／または過敏性腸管症候群に対する処置としてのｐｈｙ９０６の使用
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
CA2729582C (en) 2008-07-01 2017-09-19 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
DE102009001041A1 (de) * 2009-02-20 2010-08-26 Marien-Apotheke Fulda Ohg Notfallset zur Herstellung eines Arzneimittels zur nasalen Anwendung von Opioiden bei Atemnot
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
US9040095B2 (en) * 2009-10-14 2015-05-26 Gi Innovations, Pllc Colon cleansing of residual stool and secretions during colonoscopy
ES2623503T3 (es) * 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente
CN102918039B (zh) 2010-03-11 2017-06-09 惠氏有限责任公司 甲基纳曲酮的口服制剂和亲脂盐
US9700508B2 (en) 2010-05-10 2017-07-11 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
EP2568965A1 (en) 2010-05-10 2013-03-20 Euro-Celtique S.A. Combination of active loaded granules with additional actives
PH12012502083A1 (en) 2010-05-10 2017-07-26 Euro Celtique Sa Manufacturing of active-free granules and tablets comprising the same
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX2010012479A (es) * 2010-11-16 2012-05-16 Posi Visionary Solutions Llp Composicion farmaceutica de administracion oral para el tratamiento del sindrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retencion de gases y enzimas digestivas y proceso para su preparacion.
US8778907B2 (en) * 2011-04-27 2014-07-15 Cumberland Pharmaceuticals Lactulose for bowel evacuation
US20130237597A1 (en) * 2012-03-07 2013-09-12 Albert Duoibes Extended-release solid oral dosage form for homeopathic compositions
RU2488824C1 (ru) * 2012-03-20 2013-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ дифференциальной диагностики кишечных инфекций с синдромом гастроэнтерита и алкогольного гастроэнтерита
US10485798B2 (en) 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
CA3178035A1 (en) 2012-12-24 2014-07-03 Neurogastrx, Inc. Methods for treating gi tract disorders
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
US9044502B2 (en) * 2013-09-18 2015-06-02 Hong Kong Baptist University Chinese medicinal formulation for treating inflammatory bowel disease and the preparation thereof
RU2683781C2 (ru) * 2013-10-09 2019-04-02 Седарс-Синаи Медикал Сентер Диагностика и лечение синдрома раздраженного кишечника и воспалительного заболевания кишечника
WO2015071380A1 (en) 2013-11-13 2015-05-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
NZ730490A (en) * 2014-10-09 2021-07-30 Cedars Sinai Medical Center Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
WO2016193456A2 (en) * 2015-06-03 2016-12-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation
MX383392B (es) 2016-09-27 2025-03-13 Camurus Ab Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta).
KR102150548B1 (ko) * 2017-04-25 2020-09-01 대구한의대학교산학협력단 혼합 생약 추출물 및 설파살라진을 유효성분으로 포함하는 대장염 예방 또는 치료용 조성물
WO2018222947A1 (en) * 2017-06-01 2018-12-06 Stc.Unm Bubblyte
IT201700108039A1 (it) * 2017-09-27 2019-03-27 Neilos S R L Composizione per il trattamento della costipazione
IT201700108033A1 (it) * 2017-09-27 2019-03-27 Neilos S R L Composizione per il trattamento della costipazione
US11564970B2 (en) * 2017-10-09 2023-01-31 The Broad Institute, Inc. Compositions and methods for combinatorial drug discovery in nanoliter droplets
CN108354943A (zh) * 2018-02-13 2018-08-03 南方医科大学南方医院 新生霉素用于制备抑制trpv1表达和转运功能的药物的用途
MX2021013488A (es) * 2019-05-07 2021-12-10 Bausch Health Ireland Ltd Formulaciones liquidas de dosis oral de metilnaltrexona.
CA3142214A1 (en) * 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
CN118356457B (zh) * 2024-04-29 2025-12-12 河南中医药大学 白头翁汤在增效抗生素抗菌作用中的新用途

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
JPS5535031A (en) * 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
US4311833A (en) * 1979-03-06 1982-01-19 Daicel Chemical Industries Ltd. Process for preparing ethylcarboxymethylcellulose
US4322426A (en) * 1980-04-28 1982-03-30 E. I. Du Pont De Nemours And Company 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4987136A (en) * 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US4457907A (en) * 1982-08-05 1984-07-03 Clear Lake Development Group Composition and method for protecting a therapeutic drug
US4518433A (en) * 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4462839A (en) * 1983-06-16 1984-07-31 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4556552A (en) * 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
DE3474511D1 (en) * 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US5266574A (en) * 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
JPS6229515A (ja) * 1985-07-30 1987-02-07 Shinjiro Tsuji 硬カプセル剤のフイルムコ−テイング方法
US4719215A (en) * 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) * 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
DE3777658D1 (de) * 1986-08-28 1992-04-23 Enzacor Pty Ltd Tierwachstumserreger.
US5597564A (en) * 1986-08-28 1997-01-28 Enzacor Properties Limited Method of administering a microgranular preparation to the intestinal region of animals
US4888346A (en) * 1986-10-07 1989-12-19 Bernard Bihari Method for the treatment of persons infected with HTLV-III (AIDS) virus
US4857833A (en) * 1987-08-27 1989-08-15 Teradyne, Inc. Diagnosis of faults on circuit board
JPH01279895A (ja) * 1988-01-20 1989-11-10 Baker Cummins Pharmaceut Inc オピオイド拮抗剤のグルクロン酸誘導体
US5102887A (en) * 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
NL9002118A (nl) * 1990-09-27 1992-04-16 Medilife Holding Bv Injectiespuit.
JPH04230625A (ja) * 1990-12-27 1992-08-19 Standard Chem & Pharmaceut Corp Ltd 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法
CA2064373C (en) * 1991-03-29 2005-08-23 Buddy Eugene Cantrell Piperidine derivatives
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5270328A (en) * 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
DK0590060T3 (da) * 1991-06-21 1998-05-11 Univ Cincinnati Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling
US5614219A (en) * 1991-12-05 1997-03-25 Alfatec-Pharma Gmbh Oral administration form for peptide pharmaceutical substances, in particular insulin
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
CA2086631C (en) * 1992-12-22 1998-10-06 J. Gabriel Michael Oral administration of immunologically active biomolecules and other therapeutic proteins
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5391372A (en) * 1993-06-28 1995-02-21 Campbell; Elizabeth Methods of treating colic and founder in horses
US5434171A (en) * 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
EP0758403B1 (en) * 1994-05-05 1998-06-24 Beckman Instruments, Inc. Oligonucleotide repeat arrays
IT1269826B (it) * 1994-05-24 1997-04-15 Paolo Minoia Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
US5614422A (en) * 1995-03-17 1997-03-25 Harris Corporation Process for doping two levels of a double poly bipolar transistor after formation of second poly layer
US6025154A (en) * 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US5804595A (en) * 1995-12-05 1998-09-08 Regents Of The University Of Minnesota Kappa opioid receptor agonists
DE69709646T2 (de) * 1996-03-12 2002-08-14 Alza Corp., Palo Alto Zusammensetzung und dosisform mit einem opioid-antagonisten
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6353004B1 (en) * 1997-07-14 2002-03-05 Adolor Coporation Peripherally acting anti-pruritic opiates
US6559158B1 (en) * 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US5972954A (en) * 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
WO2001013909A2 (en) * 1999-08-25 2001-03-01 Cooper Barrett R Compositions and methods for treating opiate intolerance
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
ES2226933T3 (es) * 1999-11-01 2005-04-01 John Rhodes Composicion para tratar el estreñimiento y el sindrome del intestino irritable.
US6469030B2 (en) * 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6967075B2 (en) * 2000-04-07 2005-11-22 Schering Corporation HCV replicase complexes
ATE402908T1 (de) * 2000-06-06 2008-08-15 Trojan Techn Inc Mischvorrichtung für fluide
EP1296714B1 (en) * 2000-06-22 2009-08-26 University Of Iowa Research Foundation Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
US20030022909A1 (en) * 2001-06-05 2003-01-30 University Of Chicago Use of methylnaltrexone to treat immune suppression
ES2654819T3 (es) * 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
CA2475305A1 (en) * 2002-02-04 2004-02-19 Jonathan Moss Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
US6986901B2 (en) * 2002-07-15 2006-01-17 Warner-Lambert Company Llc Gastrointestinal compositions
WO2004054511A2 (en) * 2002-12-13 2004-07-01 The Regents Of The University Of California Analgesic combination comprising nalbuphine
CA2811272C (en) * 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
EP1638607A1 (en) * 2003-04-08 2006-03-29 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
EP1682006A4 (en) * 2003-10-29 2011-01-26 Physiosonics Inc METHOD AND DEVICE FOR DETERMINING A MIDDLE LINE OF AN ULTRASONIC LIQUID FLOW
EP1845989A1 (en) * 2005-01-20 2007-10-24 Progenics Pharmaceuticals, Inc. Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos

Similar Documents

Publication Publication Date Title
JP2006522817A5 (https=)
RU2005134359A (ru) Применение метилналтрексона для лечения синдрома раздраженного кишечника
Reimer et al. Meeting the challenges of opioid-induced constipation in chronic pain management–a novel approach
Moon Postoperative nausea and vomiting
Leppert The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review
JP2006522819A5 (https=)
NZ591859A (en) Peripheral opioid receptor antagonists and uses thereof
Horrigan et al. Management of opioid-induced constipation in older adults
CN107072988A (zh) 包含辛波莫德和拉喹莫德的用于治疗多发性硬化症的组合
JP2008526927A5 (https=)
Chan et al. Short bowel syndrome in adults—part 4-B. A guide to front line drugs used in the treatment of short bowel syndrome
Azizi et al. A review of the clinical manifestations, pathophysiology and management of opioid bowel dysfunction and narcotic bowel syndrome
Kim et al. Efficacy and safety of propiverine in children with overactive bladder
WO2010092436A1 (en) Pharmaceutical combinations of simethicone and otilonium
Deibert et al. Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation
JPH0225427A (ja) 慢性痛あるいは慢性咳を治療する経口用組成物
Patel et al. Opioids for pain after oral surgery
Neyens et al. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus
Hashizume et al. Analysis of predictive factors for diarrhea after the administration of naldemedine
EP2914267B1 (en) Therapy for constipation
Fakata et al. Peripheral Opioid Antagonists: A therapeutic advance for optimizing gastrointestinal opioid tolerability.
Kareem et al. Mu-opioid receptor antagonists and their role in treatment of chronic constipation
Uritsky Methylnaltrexone: Peripherally acting µ-opioid receptor antagonist
Sprawls et al. Drugs in development for opioid-induced constipation
US20070142367A1 (en) Method and medicine for treating gastrointestinal disorder including fecal incontinence